Clinical trials
Pharmacodynamics clinical trials
Below are recruiting pharmacodynamics clinical trials, each written for real people, not researchers. We’re tracking 160 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07179640RecruitingPhase 1/Phase 2
Testing ALE1 for hypophosphatasia in healthy people and patients
This trial tests a new medicine called ALE1 for hypophosphatasia (HPP), a rare bone condition. It first checks safety in healthy volunteers, then tests if the medicine helps people with HPP.
WürzburgAges 18–50 - NCT07182552Enrolling by invitationPhase 1
Testing a new drug NTB003 in healthy volunteers
This early-phase trial tests the safety of a new drug called NTB003 in healthy people. It looks at how the drug moves through the body and affects it, which is a first step toward possibly treating certain conditions.
BeijingAges 25–45 - NCT07161258RecruitingPhase 2
Fenebrutinib for children with relapsing MS
This study tests a new oral medication called fenebrutinib for children and teenagers with relapsing multiple sclerosis. It aims to find the right dose and see how safe and effective it is compared to standard treatments.
Rosario, Santa Fe ProvinceAges 10–17 - NCT07149454Enrolling by invitationPhase 1
Testing a new antibody to prevent tetanus
This trial tests a new medicine made from antibodies that target tetanus toxin. It may help protect people from tetanus without needing a vaccine.
Lanzhou, GansuAges 18–60 - NCT07152288RecruitingPhase 1
Study of HSK39297 in people with liver problems
This trial tests how a new drug, HSK39297, works in people with mild to moderate liver impairment (Child-Pugh A or B). It compares them to healthy volunteers to see how the liver affects the drug's safety and how the body processes it.
BeijingAges 18–70 - NCT06732180RecruitingPhase 1
Testing a new drug (GT-02287) for Parkinson's disease
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Darlinghurst, New South WalesAges 30–85 - NCT07142707RecruitingPhase 1
Testing a new obesity drug for safety and effects
This study tests an investigational medication called MBX 4291 for adults with obesity. It aims to see if the drug is safe and how it works in the body, which could lead to a new weight-loss treatment option.
Doral, FloridaAges 18–65 - NCT07128329RecruitingPhase 1
Acute effects of oral nicotine pouches
This study tests how oral nicotine pouches affect the body, including heart rate and blood pressure, in both daily smokers and people who have used very little nicotine. It helps researchers understand the immediate effects of these pouches.
Baltimore, MarylandAges 21 years+ - NCT07118085RecruitingPhase 1
Testing the safety of IMC-003 in healthy postmenopausal women
This study tests the safety of a new medicine called IMC-003. It is for healthy women who have gone through menopause. You may be able to join if you are between 45 and 75 years old and meet certain health criteria.
Chengdu, SichuanAges 45–75 - NCT06752746RecruitingPhase 1
Testing 9MW3011 for polycythemia vera in resistant patients
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
Zhengzhou, HenanAges 18 years+ - NCT07098091Enrolling by invitationPhase 1
Testing the safety of YD0293 in healthy adults
This phase 1 study tests a new medicine called YD0293 in healthy volunteers to see if it is safe and how the body handles it. It helps find the right dose for future studies.
Suzhou, JiangsuAges 18–45 - NCT07078994RecruitingPhase 2
Study of a new drug for moderate to severe Crohn's disease
This trial tests a new medicine called BCD-261 for people with moderate to severe Crohn's disease that has not responded well to other treatments. It aims to see if the drug can reduce symptoms and inflammation.
Barnaul, Altayskiy KrayAges 18–75 - NCT07085507RecruitingPhase 1/Phase 2
Testing a new drug for multiple sclerosis in healthy people and MS patients
This trial tests an experimental oral drug called VT7208 in both healthy volunteers and people with multiple sclerosis (MS). The goal is to see if it is safe and how the body processes it, which could lead to a new treatment option for MS.
Adelaide, South AustraliaAges 18–65 - NCT07080034RecruitingPhase 2
Testing BCD-261 for moderate to severe ulcerative colitis
This trial tests a new drug called BCD-261 for people with moderate to severe ulcerative colitis that hasn't gotten better with standard treatments. It aims to see if the drug can improve symptoms and how safe it is.
Barnaul, Altayskiy KrayAges 18–75 - NCT07073547RecruitingPhase 1
Study of AZD0120 for multiple myeloma patients
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
Phoenix, ArizonaAges 18 years+ - NCT07051603RecruitingPhase 1
Safety study of SAL0140 in healthy Chinese adults
This study tests the safety and how the body handles a new medicine (SAL0140) in healthy people. It helps doctors find the right dose and check for side effects.
Guangzhou, GuangdongAges 18–65 - NCT07051629RecruitingPhase 1
Testing a new epilepsy medicine for safety in healthy people and patients
This study tests a new medicine called SIF001 for safety. It first gives the medicine to healthy volunteers, and then to people with epilepsy who have seizures even while on their current medicines. The goal is to find a safe dose.
Tucson, ArizonaAges 18–70 - NCT07040930RecruitingPhase 1
Testing the safety of GenSci120 in healthy adults
This study tests a new drug called GenSci120, given as multiple injections under the skin, to see if it is safe in healthy adults. It will also measure how the drug moves through the body and how it affects certain immune markers.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT07032688RecruitingPhase 1
Study of SHR-3167 for type 2 diabetes
This trial tests an experimental drug called SHR-3167 in people with type 2 diabetes. The goal is to see how the drug works in the body and how it affects blood sugar. It may be an option for adults who have had diabetes for at least 6 months.
Chengdu, SichuanAges 18–59 - NCT07024823RecruitingPhase 1
Safety study of AZD4248 in healthy people and those with kidney disease and diabetes
This trial tests an experimental drug called AZD4248 to see if it's safe for healthy people and for people with chronic kidney disease and type 2 diabetes. It also checks if a home device can accurately measure kidney function.
Glendale, CaliforniaAges 18–75 - NCT07025148RecruitingPhase 4
Comparing two blood thinners after stenting for high-risk patients
This trial tests switching from a standard blood thinner (clopidogrel) to a lower dose of a stronger one (prasugrel) in people who have had a stent placed and are at high risk for both bleeding and heart problems. The goal is to see if the switch better prevents clots while keeping bleeding risks low.
Jacksonville, FloridaAges 18 years+ - NCT06993636Recruiting
Study of rivaroxaban in Chinese children with large heart artery bulges
This trial is testing the drug rivaroxaban in children aged 2 to 17 who have large bulges (aneurysms) in their heart arteries after Kawasaki disease. It aims to see how the drug works in the body to prevent blood clots.
Shanghai, Shanghai MunicipalityAges 2–18 - NCT07005713RecruitingPhase 1
Study of tacabrutideg for chronic spontaneous urticaria
This trial tests a new oral medication called tacabrutideg (BGB-16673) for chronic spontaneous urticaria, a condition with frequent hives and itching. It aims to see how safe it is and how well it works, possibly offering a new option for people who still have symptoms despite antihistamines.
Beijing, Beijing MunicipalityAges 18–70 - NCT07003542RecruitingPhase 2
Sitagliptin for people with high-grade brain tumors
This trial tests whether sitagliptin, a medicine usually used for diabetes, can help people with a fast-growing type of brain tumor (grade 4 glioma). You will take sitagliptin before your planned surgery, and researchers will study how it affects your tumor.
Cleveland, OhioAges 18 years+
Hear when a new Pharmacodynamics trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pharmacodynamics?
- Yes. Clin2 currently lists 160 recruiting pharmacodynamics studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pharmacodynamics trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pharmacodynamics trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.